Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
atai Life Sciences announced outcome data from a Phase 1 trial of KUR-101, a novel analgesic treatment. The trial assessed safety and analgesic activity in healthy volunteers. KUR-101 was well tolerated and showed analgesic effects in two pain models, although less effective than oxycodone. An inconclusive assessment of respiratory impact highlighted the need for further research. KUR-101 aims to provide therapeutic benefits without significant respiratory depression, potentially offering a safer alternative for treating opioid use disorder and acute pain.
atai Life Sciences N.V. (Nasdaq: ATAI) has initiated its Phase 2b proof-of-concept trial for the novel compound RL-007, targeting Cognitive Impairment Associated with Schizophrenia (CIAS). With no FDA-approved treatments available for CIAS, this randomized, placebo-controlled study aims to evaluate the pro-cognitive effects of RL-007 among 234 patients. The trial is underway with expectations for topline results in H1 2024. RL-007 has shown positive outcomes in prior studies and could address a significant unmet need in mental health treatment.
atai Impact has announced the launch of the first cohort from its $2 million Fellowship Fund in Psychedelic Neuroscience at Massachusetts General Hospital. The fund aims to support research into psychedelics for mental health treatment and foster the careers of promising graduate students. The selected fellows will explore various aspects of psychedelics, including biochemical studies and potential therapeutic interventions. This initiative reflects atai's commitment to advancing mental health through innovative research and educational opportunities.
atai Life Sciences has appointed Dr. Kirpekar as Chief Business Officer, effective immediately. Previously, Dr. Kirpekar served as Head of Business Development at Otsuka Pharmaceutical, where he was involved in transactions over USD 2.7 billion. In his new role, he will guide atai's pipeline strategy and global business development efforts. Dr. Kirpekar's extensive experience in CNS and digital health, along with his background in bringing therapies to market, positions him to strengthen atai's initiatives in mental health treatment.
atai Life Sciences (NASDAQ: ATAI) has launched a clinical study in collaboration with Massachusetts General Hospital (MGH) focusing on treatment-resistant depression (TRD). The study aims to identify neuroplasticity biomarkers using neuroimaging techniques during IV ketamine treatment. By assessing brain changes, the research seeks to advance understanding of treatment responses and efficacy. Given that treatment-resistant patients account for a significant portion of annual mental healthcare spending in the U.S., the findings could be pivotal for personalized mental health treatments based on neuroplasticity.
atai Life Sciences announced significant advancements in its clinical trials for mental health therapies. The Phase 2a trial of PCN-101 for treatment-resistant depression (TRD) has completed dosing, with topline results expected by year-end 2022. Positive preliminary results were reported for GRX-917 in generalized anxiety disorder and KUR-101 for opioid use disorder. The company ended Q3 2022 with a cash position of $304 million, providing a runway into 2025, despite a net loss of $33.9 million for the quarter. Future trials and potential market impact were highlighted.
The Women in Psychedelics Network (WIPN) announced atai Life Sciences (NASDAQ: ATAI) as a platinum sponsor through atai Impact. This partnership emphasizes mutual support for women's leadership in the psychedelic industry and mental health advancements. WIPN aims to enhance women’s roles via educational events, mentorship, and funding opportunities. Rae Richman from atai highlighted their commitment to diversity and inclusion while Sarah Popham emphasized the importance of WIPN's work for women in psychedelics. The collaboration aligns with atai's mission to address mental health challenges.
atai Life Sciences (Nasdaq: ATAI) will participate in several investor events and healthcare conferences in November 2022. Key events include:
- Financial Times Pharma and Biotech Summit on November 9, 2022, 9:55 a.m. ET
- Credit Suisse Annual Healthcare Conference on November 9, 2022, 4:35 p.m. ET
- HLTH in Las Vegas on November 14, 2022, 7:20 p.m. ET
- Jefferies Healthcare Conference on November 16, 2022, 8:00 a.m. GMT
- CNS Summit in Boca Raton on November 19, 2022, 12:00 p.m. ET
Archived webcasts will be available on the company's website for 90 days.
atai Life Sciences (Nasdaq: ATAI) will announce its Q3 2022 financial results and provide a business update on November 10, 2022. The announcement comes as atai continues its mission to innovate treatments for mental health disorders. A management interview will be accessible at 8:30 a.m. ET, providing insights into the company's progress and future outlook. Founded in 2018, atai is focused on developing therapeutics for depression, anxiety, and addiction.
atai Life Sciences (NASDAQ: ATAI) has completed enrollment for its Phase 2a clinical trial evaluating PCN-101 (R-ketamine) for treatment-resistant depression (TRD). Targeting around 100 patients who have not responded to previous antidepressants, the randomized, double-blind study is expected to yield topline results by year-end 2022. This trial is significant as PCN-101 may provide rapid-acting treatment options for TRD, allowing for at-home patient administration. The completion of enrollment marks a critical milestone in developing innovative therapeutic solutions for mental health disorders.